Francisco Javier Esteva, MD, discusses therapeutic advances for patients with HER2-positive breast cancer.
Francisco Javier Esteva, MD, PhD, chair of breast oncology, Northwell Health Cancer Institute, discusses therapeutic advances for patients with HER2-positive breast cancer.
Historically, patients with HER2-positive breast cancer have a poor outlook, according to Estiva. With the development of drugs such as trastuzumab (Herceptin), pertuzumab (Perjeta), neratinib (Nerlinx), and ado trastuzumab emtancin (T-DM1; Kadsilla), these patients now have significantly improved outcomes. However, it’s important to understand how these factors are sequenced and combined for maximum benefit, Esteva says.
Esteva explains that incorporating new adjuvant therapy into a treatment plan is important for patients with early-stage and high-risk breast cancer. Esteva concludes that once patients have been identified who do not achieve a complete satisfactory response to this approach, additional treatments can be used to improve outcomes.